Tumor protein 53 gene polymorphism, demographic attributes and associated risk factors among liver cancer patients in Calabar, Nigeria
- PMID: 40065269
- PMCID: PMC11892161
- DOI: 10.1186/s12885-025-13803-y
Tumor protein 53 gene polymorphism, demographic attributes and associated risk factors among liver cancer patients in Calabar, Nigeria
Abstract
Mutations in the TP53 gene had been attributed to the development of liver cancer. Hepatocellular carcinoma (HCC) and liver tumour are liver diseases having high mortality rates in several populations. There is no information on the TP53 gene polymorphism among liver diseases patients in Calabar, Nigeria. This study investigated the genetic polymorphism of TP53 among HCC and liver tumour in Calabar. This research was carried out in the University of Calabar Teaching Hospital, Calabar. Blood samples were collected from 35 clinically diagnosed hepatocellular carcinoma and 10 tumour patients and 10 healthy controls. DNA was extracted from all blood samples and Polymerase Chain Reaction (PCR) was performed using specific primers. The PCR amplicons were digested using Hae III restriction enzyme and the genotypic and allelic frequencies was determined. Demographic data among participants showed that males were 68.9% (31), females (31.1%; 14), sex ratio (2.2: 0.5), mean age was 41.51 ± 2.13 years with an odds ratio of 1.25. The distribution of participants according to marital status were 33(73.3%), 10(22.2%), and 2(4.4%) for married, single, and widowed respectively. The participants were from different extractions with varied representations of Yakurr (22.2%, 10), Efik (20%, 9), Boki (13.3%, 6), Ogoja (13.3%, 6), Annang (8.8%, 4), Ibibio (2.2%, 1) and Igbo (2.2%, 1) and respectively. Approximately, 64.7% (30) of the chronic liver diseases were from the Central and Northern part of Cross River State. The risk factors were HCV infection, HBsAg+, alcoholism, smoking, consumption of groundnuts that may have been contaminated with aflatoxin and family history of the disease. PCR product yielded 254 bp and digested PCR product showed homozygous TT mutation (27), heterozygous GT mutation (17) and homozygous GG wild type (1) in cases. The overall TP53 gene mutation frequency was 46.32% (44). The frequency of G allele, T allele, GG, GT and TT were 0.21, 0.79, 0.04, 0.33 and 0.62 respectively among cases, while GG (wild type) was only detected among controls in the study population. The genotypic and allelic frequencies conform to Hardy-Weinberg equilibrium meaning that the forces of evolution were not acting on the locus. There were significant differences in the genotypic proportions of the TP53 gene polymorphism among patients and controls. This study on the TP53 gene polymorphism will serve as baseline information on the molecular etiology of hepatocellular carcinoma and liver tumour in Cross River State.
Keywords: Hepatocellular carcinoma; Liver tumour; Mutations; Patients; Tumor protein gene.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Ethical approval was obtained from the University of Calabar Teaching Hospital Ethical Review Committee before the commencement of this study. The approval is given by the Cross River State Ministry of Health Committee on Ethical approval for all research involving human subjects. The approval no. was CRS/MOH/EAC/ARP/20/038. This approval takes into consideration the World Medical Association (WMA) stance as posited by Helsinki declaration regarding the protection of the patients’ health, the quest for the knowledge of liver cancer and override or trample upon the patients’ fundamental rights, consideration of risks, burdens and benefits and focus on ethics by following local regulatory norms while protecting the patient’s privacy and confidentiality. The informed consent of the patients and their caregivers was sought and obtained prior to their inclusion into study. Consent for publication: “Not applicable”. Competing interests: The authors declare no competing interests.
Figures


References
-
- Ferlay J, Colombet M, Soerjomataram I. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. - PubMed
-
- Llovet JM, Villanueva A.. Effect of HCV clearance with direct- acting antiviral agents on HCC. Nature Review inGastroenterology and Hepatology, 2016;13:561–562. - PubMed
-
- Llovet JM, Zucman-Rossi J, Pikarsky E. Hepatocellular carcinoma. Nat Revision Disease Primers. 2016;(1):16018–22. - PubMed
-
- Igetei R, Otegbayo JA, Ndububa DA, Lesi OA, Anumudu CI, Hainaut P, Gormally E. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol. 2008;7:339–44. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous